RCTs Galore: The Evidence We Have, The Answers We Don’t

Co-Moderator(s)

• 

  Vlad Simianu, MD MPH

  Medical Director, Colon and Rectal Disorders
  Virginia Mason Medical Center
  Seattle, Washington, United States

  All of the relevant financial relationships listed below have been mitigated.
  This individual has no financial relationships with ineligible companies.
• MK

  Mary Kwaan, MD, MPH (she/her/hers)

  Health Sciences Clinical Professor of Surgery
  David Geffen School of Medicine at UCLA
  David Geffen School of Medicine at UCLA
  --, California, United States

  All of the relevant financial relationships listed below have been mitigated.
  This individual has no financial relationships with ineligible companies.

CME: .75 hours

This 50-minute symposium, "RCTs Galore: The Evidence We Have, The Answers We Don’t," is tailored for colorectal surgeons, focusing on recent randomized controlled trials (RCTs) that have shaped clinical practice while also highlighting persistent knowledge gaps. The session will begin with a discussion on the ANCHOR trial, exploring its success in anal cancer prevention and the challenges of extrapolating high-resolution anoscopy to the broader at-risk population. Next, the symposium will examine the widespread adoption of indocyanine green (ICG) fluorescent angiography for assessing anastomotic perfusion, reviewing the current trial evidence, and discussing whether its use is justified despite the lack of definitive outcome data. Finally, the session will address the evolving role of neoadjuvant chemotherapy for colon cancer, summarizing the benefits and limitations of this approach and discussing the critical question of when and for whom it should be considered. By the end of this symposium, attendees will be able to describe challenges in applying anal cancer prevention strategies, review the current evidence on ICG, and summarize the benefits and limitations of neoadjuvant chemotherapy for colon cancer.

Presentations:

• 9:10 AM - 9:13 AM ET

  Introduction to Symposium
• 9:13 AM - 9:14 AM ET

  Introduction to Dr. Madoff
  

  Faculty: Vlad V. Simianu, MD MPH – Virginia Mason Medical Center
• 9:14 AM - 9:22 AM ET

  The Anchor Trial and Anal Cancer Prevention: Success, But at What Scale
  

  Faculty: Robert D. Madoff, MD, FACS, FASCRS, FRCSEdHon) (he/him/his) – University of Minnesota
• 9:22 AM - 9:23 AM ET

  Introduction to Dr. Jafari.
  

  Faculty: Mary R. Kwaan, MD, MPH (she/her/hers) – David Geffen School of Medicine at UCLA
• 9:23 AM - 9:31 AM ET

  ICG for anastomotic perfusion: adoption despite the evidence?
  

  Faculty: Mehraneh D. Jafari, MD (she/her/hers) – Weill Cornell Medicine
• 9:31 AM - 9:32 AM ET

  Introduction to Dr. Herzig
  

  Faculty: Vlad V. Simianu, MD MPH – Virginia Mason Medical Center
• 9:32 AM - 9:40 AM ET

  Neoadjuvant Chemotherapy for Colon Cancer: When and for Whom?
  

  Faculty: Daniel Herzig, MD – Knight Cancer Institute, Oregon Health and Science University
• 9:40 AM - 10:00 AM ET

  Polling, Questions, and Discussion